Strategic partnerships Sintetica has a history of collaborations with distributors and healthcare groups (FFF Enterprises US exclusive partner for Lidocaine Injection; EIT Health collaboration), suggesting sales opportunities through distribution partnerships and co-marketing arrangements to expand U.S. and European reach.

Product launch momentum Recent launch of Lidocaine Hydrochloride Injection under Sintetica US indicates a capability to bring injectable products to market quickly. Leverage this by pitching additional anesthetic, pain management, or neuromodulation injectables and related contract manufacturing or supply deals.

Therapy focus Core focus areas include anaesthesia, pain management, intensive care and neuromodulation. Target opportunities with hospitals, surgical centers, and ICU networks seeking specialized injectable therapies and related supply continuity.

Regional expansion potential Swiss headquarters with global partnerships imply flexibility for regional manufacturing or co-development across EMEA and beyond. Propose local manufacturing, fill-finish, or regulatory support services to broaden Sintetica’s regional footprint.

Financial and scale cues Revenue in the tens of millions and an employee base in the hundreds position Sintetica as a mid-sized specialist partner. Approach for value-driven contracts, preferred supplier agreements, and scalable manufacturing capacity aligned to mid-market pharmaceutical customers.